» Articles » PMID: 37697332

Impact of Chemotherapeutic Agents on Liver Microenvironment: Oxaliplatin Create a Pro-metastatic Landscape

Overview
Publisher Biomed Central
Specialty Oncology
Date 2023 Sep 11
PMID 37697332
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Chemotherapeutic agents are used to control tumor proliferation. However, their influence in the pre-metastatic niche of target organs has not been well studied. Oxaliplatin (OXA) is a drug applied in standard treatments of colorectal cancer (CRC), while the direct effect of which on the pre-metastatic microenvironment of the liver remains unclear.

Methods: Models of liver metastases were established with luciferase expressing CT26 cells in BALB/c and BALB/c-nude mice. Single-cell RNA Sequencing was performed to examine the immune microenvironment in the liver elicited by OXA. Immunofluorescence and flowcytometry were utilized to confirm the changes in the number of immune cells. LDH, CellTrace CFSE Cell Proliferation and apoptosis assays were conducted to explore the impact of OXA on T cells ex vivo. The correlation between chemotherapy-related lymphopenia and metastases was assessed by meta-analysis.

Results: Herein we discovered that administration of OXA prior to the occurrence of liver metastasis actually accelerated tumor development and colonization in the liver. Single-cell RNA sequencing revealed that the landscape of the liver immune microenvironment had been changed to immunosuppressive phenotype. Macrophages after the treatment of OXA exhibited a high ability to inhibit the activation of T cells. Further investigation revealed a significant decrease in the number of T cells in the liver, particularly CD8 T cells with reduced capacity of proliferation, activation, and killing. When mice were treated with T cell supplementation, the OXA-induced metastasis was notably abolished, indicating that the OXA-primed liver microenvironment could be reversed by the infusion of T cells. Consistent with our findings in mice, a meta-analysis was performed to verify that chemotherapy-related lymphopenia was associated with an inferior prognosis related with high incidence of metastasis, suggesting the pivotal role of chemotherapy in pre-metastatic niche formation. Furthermore, a notable reduction in the count of both macrophages and T cells was observed in the liver of colorectal cancer (CRC) patient undergoing OXA-based chemotherapy.

Conclusions: Our findings proposed that immunosuppressive microenvironment in liver induced by OXA enhanced liver metastasis of colorectal cancer, which highlighted a new consideration to balance the pro metastases and anti-cancer possibility of OXA treatment.

Citing Articles

Analyze the Diversity and Function of Immune Cells in the Tumor Microenvironment From the Perspective of Single-Cell RNA Sequencing.

Ma L, Luan Y, Lu L Cancer Med. 2025; 14(5):e70622.

PMID: 40062730 PMC: 11891933. DOI: 10.1002/cam4.70622.


Immune dynamics shaping pre-metastatic and metastatic niches in liver metastases: from molecular mechanisms to therapeutic strategies.

Zhu C, Liao J, Liu Y, Chen Z, Chang R, Chen X Mol Cancer. 2024; 23(1):254.

PMID: 39543660 PMC: 11562679. DOI: 10.1186/s12943-024-02171-z.


Huaier promotes sensitivity of colorectal cancer to oxaliplatin by inhibiting METTL3 to regulate the Wnt/β‑catenin signaling pathway.

Huo M, Gao Z, Wang G, Hou Z, Zheng J Oncol Rep. 2024; 53(1).

PMID: 39513580 PMC: 11574703. DOI: 10.3892/or.2024.8840.


Pre-metastatic niche: formation, characteristics and therapeutic implication.

Wang Y, Jia J, Wang F, Fang Y, Yang Y, Zhou Q Signal Transduct Target Ther. 2024; 9(1):236.

PMID: 39317708 PMC: 11422510. DOI: 10.1038/s41392-024-01937-7.


Role of T cells in liver metastasis.

Wu K, Zhang G, Shen C, Zhu L, Yu C, Sartorius K Cell Death Dis. 2024; 15(5):341.

PMID: 38755133 PMC: 11099083. DOI: 10.1038/s41419-024-06726-2.


References
1.
Lee G, Kim D, Muralidhar V, Mitra D, Horick N, Eyler C . Chemoradiation-Related Lymphopenia and Its Association with Survival in Patients with Squamous Cell Carcinoma of the Anal Canal. Oncologist. 2020; 25(12):1015-1022. PMC: 7938411. DOI: 10.1634/theoncologist.2019-0759. View

2.
Kim E, Kim T, Jung W, Kim K, Chang A, Park H . Prognostic impact of neutrophilia and lymphopenia on survival in anal cancer treated with definitive concurrent chemoradiotherapy: a retrospective multicenter study. Int J Clin Oncol. 2021; 27(3):553-562. DOI: 10.1007/s10147-021-02094-5. View

3.
Mendez J, Govindan A, Leong J, Gao F, Huang J, Campian J . Association between treatment-related lymphopenia and overall survival in elderly patients with newly diagnosed glioblastoma. J Neurooncol. 2016; 127(2):329-35. PMC: 4783226. DOI: 10.1007/s11060-015-2037-1. View

4.
Wild A, Ye X, Ellsworth S, Smith J, Narang A, Garg T . The Association Between Chemoradiation-related Lymphopenia and Clinical Outcomes in Patients With Locally Advanced Pancreatic Adenocarcinoma. Am J Clin Oncol. 2013; 38(3):259-65. PMC: 3991773. DOI: 10.1097/COC.0b013e3182940ff9. View

5.
Nakano H, Oussoultzoglou E, Rosso E, Casnedi S, Chenard-Neu M, Dufour P . Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg. 2007; 247(1):118-24. DOI: 10.1097/SLA.0b013e31815774de. View